GSK reports positive results from DREAMM-8 phase III trial for Blenrep vs standard of care combination in relapsed/refractory MM

GSK plc announced positive interim results from the DREAMM-8 phase III trial, comparing Blenrep (belantamab mafodotin) plus pomalidomide and dexamethasone (PomDex) against bortezomib plus PomDex for relapsed or refractory multiple myeloma. Meeting its primary endpoint of progression-free survival (PFS) in an interim analysis, the trial was unblinded early at the recommendation of the Independent Data Monitoring Committee (IDMC). Belantamab mafodotin significantly extended progression-free survival compared to the standard treatment, with a favourable trend in overall survival (OS). Safety profiles were consistent with individual agent profiles. This is the second positive phase III trial for belantamab mafodotin combinations in this treatment setting, following DREAMM-7. Detailed results will be presented at a medical congress. Multiple myeloma, the third most common blood cancer globally, poses challenges due to treatment resistance, necessitating continued research into new therapies. Blenrep is an antibody-drug conjugate incorporating a humanized B-cell maturation antigen monoclonal antibody linked to auristatin F via a non-cleavable linker.